These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37530627)

  • 21. New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors.
    Gangat N; Tefferi A
    Am J Hematol; 2024 May; 99(5):978-981. PubMed ID: 38332640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety of JAK kinase inhibitors for the treatment of myelofibrosis.
    Coltro G; Vannucchi AM
    Expert Opin Drug Saf; 2021 Feb; 20(2):139-154. PubMed ID: 33327810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what's the current standard of care?
    Swaminathan M; Jain A; Choi SD; Pemmaraju N
    Expert Rev Hematol; 2024 Nov; 17(11):769-780. PubMed ID: 39344987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
    Mesa RA; Hudgens S; Floden L; Harrison CN; Palmer J; Gupta V; McLornan DP; McMullin MF; Kiladjian JJ; Foltz L; Platzbecker U; Fox ML; Mead AJ; Ross DM; Oh ST; Perkins A; Leahy MF; Deheshi S; Donahue R; Klencke BJ; Verstovsek S
    Cancer Med; 2023 May; 12(9):10612-10624. PubMed ID: 37021939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pacritinib: a new agent for the management of myelofibrosis?
    Beauverd Y; McLornan DP; Harrison CN
    Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
    Koschmieder S; Isfort S; Schulte C; Jacobasch L; Geer T; Reiser M; Koenigsmann M; Heinrich B; Wehmeyer J; von der Heyde E; Tesch H; Gröschl B; Bachhuber P; Großer S; Pahl HL
    Ann Hematol; 2023 Dec; 102(12):3383-3399. PubMed ID: 37792065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
    Zhang Y; Zhou H; Duan M; Gao S; He G; Jing H; Li J; Ma L; Zhu H; Chang C; Du X; Hong M; Li X; Liu Q; Wang W; Xu N; Yang H; Lu B; Yin H; Wu L; Suo S; Zhao Q; Xiao Z; Jin J
    Am J Hematol; 2023 Oct; 98(10):1588-1597. PubMed ID: 37470365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
    Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
    Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
    Mascarenhas J; Harrison C; Schuler TA; Liassou D; Garretson M; Miller TA; Mahadevan S; McBride A; Tang D; DeGutis IS; Abraham P; Kish J; Feinberg BA; Gerds AT
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):122-132. PubMed ID: 37839939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
    Mesa R; Harrison C; Oh ST; Gerds AT; Gupta V; Catalano J; Cervantes F; Devos T; Hus M; Kiladjian JJ; Lech-Maranda E; McLornan D; Vannucchi AM; Platzbecker U; Huang M; Strouse B; Klencke B; Verstovsek S
    Leukemia; 2022 Sep; 36(9):2261-2268. PubMed ID: 35869266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
    Loscocco GG; Vannucchi AM
    Int J Hematol; 2022 May; 115(5):626-644. PubMed ID: 35352288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
    Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
    Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
    Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Jourdan E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Shen J; Berry T; Brownstein C; Mesa RA
    Am J Hematol; 2020 Jun; 95(6):594-603. PubMed ID: 32129512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
    Verstovsek S; Kiladjian JJ; Vannucchi AM; Mesa RA; Squier P; Hamer-Maansson JE; Harrison C
    Cancer; 2023 Jun; 129(11):1681-1690. PubMed ID: 36840971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
    Gupta V; Oh S; Devos T; Dubruille V; Catalano J; Somervaille TCP; Platzbecker U; Giraldo P; Kosugi H; Sacha T; Mayer J; Illes A; Ellis C; Wang Z; Gonzalez Carreras FJ; Strouse B; Mesa R
    Leuk Lymphoma; 2024 Jul; 65(7):965-977. PubMed ID: 38501751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How I individualize selection of JAK inhibitors for patients with myelofibrosis.
    Masarova L; Chifotides HT
    Blood; 2024 Oct; ():. PubMed ID: 39357058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Zhang J; Sy O; Mesa RA
    Br J Haematol; 2022 Jul; 198(2):317-327. PubMed ID: 35476316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
    Saleh K; Ribrag V
    Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.